Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ganymed’s IMAB362 Receives Orphan Designation | Contract Pharma

What are you searching for?

Sign in

Ganymed’s IMAB362 Receives Orphan Designation

Phase IIb drug offers potential to target only cancer cells

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ganymed Pharmaceuticals’ IMAB362 for the treatment of pancreatic cancer has been granted orphan drug designation by the FDA and EMA. IMAB362 is a monoclonal antibody currently in Phase IIb development for gastroesophageal cancer.
 
IMAB362 selectively binds to the protein CLDN18.2, which is expressed in approximately 60% of primary and metastatic pancreatic cancers and approximately 80% of gastroesophageal cancers, as well as other solid tumors. The drug represents an advantage in that CLDN18.2 is absent from the vast majority of healthy tissues and therefore only targets cancerous cells.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters